Human papillomavirus genotype-specific risks for cervical intraepithelial lesions
Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 d...
Published in: | Human Vaccines & Immunotherapeutics |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Taylor & Francis Group
2021
|
Subjects: | |
Online Access: | https://doi.org/10.1080/21645515.2020.1814097 https://doaj.org/article/1a3132436787418e979345f5da26171f |
id |
ftdoajarticles:oai:doaj.org/article:1a3132436787418e979345f5da26171f |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:1a3132436787418e979345f5da26171f 2023-10-09T21:52:49+02:00 Human papillomavirus genotype-specific risks for cervical intraepithelial lesions Mari Nygård Bo T. Hansen Susanne K. Kjaer Maria Hortlund Laufey Tryggvadóttir Christian Munk Camilla Lagheden Lara G. Sigurdardottir Suzanne Campbell Kai-Li Liaw Joakim Dillner 2021-04-01T00:00:00Z https://doi.org/10.1080/21645515.2020.1814097 https://doaj.org/article/1a3132436787418e979345f5da26171f EN eng Taylor & Francis Group http://dx.doi.org/10.1080/21645515.2020.1814097 https://doaj.org/toc/2164-5515 https://doaj.org/toc/2164-554X 2164-5515 2164-554X doi:10.1080/21645515.2020.1814097 https://doaj.org/article/1a3132436787418e979345f5da26171f Human Vaccines & Immunotherapeutics, Vol 17, Iss 4, Pp 972-981 (2021) denmark high-risk hpv iceland liquid-based cytology low-risk hpv norway population-based prevalence sweden Immunologic diseases. Allergy RC581-607 Therapeutics. Pharmacology RM1-950 article 2021 ftdoajarticles https://doi.org/10.1080/21645515.2020.1814097 2023-09-24T00:35:11Z Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18–51 years before HPV vaccination era (V501-033; NCT01077856). Prevalence of HPV16 was 4.9% (95% CI: 4.4–5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5–16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5–15.4), with PPV of 8.0% (95% CI: 6.8–9.3) and OR 23.7 (95% CI: 16.0–63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8–9.2) with PPV of 4.4% (95% CI: 3.3–5.7) and OR of 2.9 (95% CI: 2.0–4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1–3.9), and OR 1.5 (95% CI: 1.1–2.2.) for high-grade cytology. These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits. Article in Journal/Newspaper Iceland Directory of Open Access Journals: DOAJ Articles Norway Human Vaccines & Immunotherapeutics 17 4 972 981 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
denmark high-risk hpv iceland liquid-based cytology low-risk hpv norway population-based prevalence sweden Immunologic diseases. Allergy RC581-607 Therapeutics. Pharmacology RM1-950 |
spellingShingle |
denmark high-risk hpv iceland liquid-based cytology low-risk hpv norway population-based prevalence sweden Immunologic diseases. Allergy RC581-607 Therapeutics. Pharmacology RM1-950 Mari Nygård Bo T. Hansen Susanne K. Kjaer Maria Hortlund Laufey Tryggvadóttir Christian Munk Camilla Lagheden Lara G. Sigurdardottir Suzanne Campbell Kai-Li Liaw Joakim Dillner Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
topic_facet |
denmark high-risk hpv iceland liquid-based cytology low-risk hpv norway population-based prevalence sweden Immunologic diseases. Allergy RC581-607 Therapeutics. Pharmacology RM1-950 |
description |
Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18–51 years before HPV vaccination era (V501-033; NCT01077856). Prevalence of HPV16 was 4.9% (95% CI: 4.4–5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5–16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5–15.4), with PPV of 8.0% (95% CI: 6.8–9.3) and OR 23.7 (95% CI: 16.0–63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8–9.2) with PPV of 4.4% (95% CI: 3.3–5.7) and OR of 2.9 (95% CI: 2.0–4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1–3.9), and OR 1.5 (95% CI: 1.1–2.2.) for high-grade cytology. These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits. |
format |
Article in Journal/Newspaper |
author |
Mari Nygård Bo T. Hansen Susanne K. Kjaer Maria Hortlund Laufey Tryggvadóttir Christian Munk Camilla Lagheden Lara G. Sigurdardottir Suzanne Campbell Kai-Li Liaw Joakim Dillner |
author_facet |
Mari Nygård Bo T. Hansen Susanne K. Kjaer Maria Hortlund Laufey Tryggvadóttir Christian Munk Camilla Lagheden Lara G. Sigurdardottir Suzanne Campbell Kai-Li Liaw Joakim Dillner |
author_sort |
Mari Nygård |
title |
Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
title_short |
Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
title_full |
Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
title_fullStr |
Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
title_full_unstemmed |
Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
title_sort |
human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
publisher |
Taylor & Francis Group |
publishDate |
2021 |
url |
https://doi.org/10.1080/21645515.2020.1814097 https://doaj.org/article/1a3132436787418e979345f5da26171f |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Human Vaccines & Immunotherapeutics, Vol 17, Iss 4, Pp 972-981 (2021) |
op_relation |
http://dx.doi.org/10.1080/21645515.2020.1814097 https://doaj.org/toc/2164-5515 https://doaj.org/toc/2164-554X 2164-5515 2164-554X doi:10.1080/21645515.2020.1814097 https://doaj.org/article/1a3132436787418e979345f5da26171f |
op_doi |
https://doi.org/10.1080/21645515.2020.1814097 |
container_title |
Human Vaccines & Immunotherapeutics |
container_volume |
17 |
container_issue |
4 |
container_start_page |
972 |
op_container_end_page |
981 |
_version_ |
1779315999091195904 |